Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory

Tito R Mendoza, Xin Shelley Wang, Charles Lu, Guadalupe R Palos, Zhongxing Liao, Gary M Mobley, Shitij Kapoor, Charles S Cleeland, Tito R Mendoza, Xin Shelley Wang, Charles Lu, Guadalupe R Palos, Zhongxing Liao, Gary M Mobley, Shitij Kapoor, Charles S Cleeland

Abstract

We conducted a study to establish the psychometric properties of a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with lung cancer (MDASI-LC). The MDASI measures 13 common "core" symptoms of cancer and its treatment. The MDASI-LC includes the 13 core MDASI symptom items and three lung cancer-specific items: coughing, constipation, and sore throat. MDASI-LC items were administered to three cohorts of patients with lung cancer undergoing either chemotherapy or chemoradiotherapy. Known-group validity and criterion (concurrent) validity of the MDASI-LC were evaluated using the Eastern Cooperative Oncology Group performance status and the 12-item Short-Form Health Survey. The internal consistency and test-retest reliability of the module were adequate, with Cronbach coefficient α-values of 0.83 or higher for all module items and subscales. The sensitivity of the MDASI-LC to changes in patient performance status (disease progression) and to continuing cancer treatment (effects of treatment) was established. Cognitive debriefing of a subset of participants provided evidence for content validity and indicated that the MDASI core items and three additional lung cancer-specific items were clear, relevant to patients, and easy to understand; only two patients suggested additional symptom items. As expected, the item "sore throat" was sensitive only for patients receiving chemoradiotherapy. The MDASI-LC is a valid, reliable, and sensitive symptom-assessment instrument whose use can enhance clinical studies of symptom status in patients with lung cancer and epidemiological and prevalence studies of symptom severity across various cancer types.

Conflict of interest statement

Disclosures: Tito R. Mendoza: None; Xin Shelley Wang: None; Charles Lu: None; Guadalupe R. Palos: None; Zhongxing Liao: None; Gary M. Mobley: None; Shitij Kapoor: None; Charles S. Cleeland: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers.

References

    1. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;37:16–21.
    1. Soni MK, Cella D, Masters GA, et al. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer. 2002;4:153–160.
    1. Cella D. Quality of life considerations in patients with advanced lung cancer. Semin Oncol. 2004;31(6 suppl 11):16–20.
    1. Sarna L, Riedinger MS. Assessment of quality of life and symptom improvement in lung cancer clinical trials. Semin Oncol. 2004;31(3 suppl 9):1–10.
    1. Wang XS, Shi Q, Lu C, et al. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 2010;116:137–145.
    1. Glare PA, Sinclair CT. Palliative medicine review: prognostication. J Palliat Med. 2008;11:84–103.
    1. Gotay CC, Kawamoto CT, Bottomley A, et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355–1363.
    1. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199–220.
    1. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A:635–642.
    1. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol. 2006;24:1459–1473.
    1. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS) Eur J Cancer. 1993;29A(suppl 1):S51–S58.
    1. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89:1634–1646.
    1. Armstrong TS, Mendoza T, Gning I, et al. Validation of the M. D. Anderson Symptom Inventory brain tumor module (MDASI-BT) J Neurooncol. 2006;80:27–35.
    1. Gning I, Trask PC, Mendoza TR, et al. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology. 2009;76:59–68.
    1. Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson Symptom Inventory, head and neck module. Head Neck. 2007;29:923–931.
    1. Wang XS, Williams LA, Eng C, et al. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI) Cancer. 2010;116:2053–2063.
    1. Fadol A, Mendoza T, Gning I, et al. Psychometric testing of the MDASI-HF: a symptom assessment instrument for patients with cancer and concurrent heart failure. J Card Fail. 2008;14:497–507.
    1. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.
    1. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277–284.
    1. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233.
    1. Statistical Package for the Social Sciences, version 16.0. Chicago: SPSS, Inc.; 2007.
    1. Nunnally JC, Bernstein IH. Psychometric Theory. 3rd ed. New York: McGraw-Hill; 1994.
    1. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
    1. Cohen J. A power primer. Psychol Bull. 1992;112:155–159.
    1. Sloan JA, Vargas-Chanes D, Kamath CC, et al. Detecting worms, ducks, and elephants: a simple approach for defining clinically relevant effects in quality-of-life measures. J Cancer Integr Med. 2003;1:41–47.
    1. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186–1196.
    1. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research et al. Washington, DC: U.S. Department of Health and Human Services; 2009. [Accessed December 18, 2009]. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available at .
    1. Lin CC, Chang AP, Cleeland CS, et al. Taiwanese version of the M. D. Anderson Symptom Inventory: symptom assessment in cancer patients. J Pain Symptom Manage. 2007;33:180–188.
    1. Mystakidou K, Cleeland C, Tsilika E, et al. Greek M. D. Anderson Symptom Inventory: validation and utility in cancer patients. Oncology. 2004;67:203–210.
    1. Nejmi M, Cleeland CS, Mendoza TR, et al. Validation and application of the Arabic version of the M. D. Anderson Symptom Inventory (MDASI-A) in Moroccan patients with cancer. J Pain Symptom Manage. 2010;40:75–86.
    1. Okuyama T, Wang XS, Akechi T, et al. Japansese version of the M. D. Anderson Symptom Inventory: a validation study. J Pain Symptom Manage. 2003;26:1093–1104.
    1. Wang XS, Wang Y, Guo H, et al. Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer. 2004;101:1890–1901.
    1. Wang XS, Laudico AV, Guo H, et al. Filipino version of the M. D. Anderson Symptom Inventory: validation and multisymptom measurement in cancer patients. J Pain Symptom Manage. 2006;31:542–552.
    1. Yun YH, Mendoza TR, Kang IO, et al. Validation study of the Korean version of the M. D. Anderson Symptom Inventory. J Pain Symptom Manage. 2006;31:345–352.
    1. Wang XS, Cleeland CS, Mendoza TR, et al. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst. 2010;102:732–738.
    1. Wang XS, Fairclough DL, Liao Z, et al. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol. 2006;24:4485–4491.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner